Frovatriptan, sold under the brand name Frova, is a triptan drug developed by Vernalis for the treatment of migraine headaches[1] and for short term prevention of menstrual migraine.[2] The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[3]
^Allais G, Benedetto C (2016). "Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine". Drug Design, Development and Therapy. 10: 3225–3236. doi:10.2147/DDDT.S105932. PMC 5055118. PMID 27757013.
^MacGregor EA (2014). "A review of frovatriptan for the treatment of menstrual migraine". International Journal of Women's Health. 6: 523–35. doi:10.2147/IJWH.S63444. PMC 4039425. PMID 24904224.
^"Frova". Vernalis. Archived from the original on 2007-09-27. Retrieved 2007-11-28.
Frovatriptan, sold under the brand name Frova, is a triptan drug developed by Vernalis for the treatment of migraine headaches and for short term prevention...
"EHMTI-0052. Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks...
receptor agonist for the treatment of migraine, later known as VML251 and frovatriptan. Vanguard Medica acquired privately held Cerebrus in 1999, which specialised...
e. sumatriptan, almotriptan, zolmitriptan, naratriptan, eletriptan, frovatriptan and rizatriptan) are also agonists at the 5-HT1D receptor, which contributes...
blood plasma levels are increased by strong inhibitors of CYP3A4, and frovatriptan levels by CYP1A2 inhibitors such as fluvoxamine. Their action is attributed...
Global Information
(what is this?) (verify)